Minakem Corporation

Minakem Corporation is a French company focused on the development and production of Active Pharmaceutical Ingredients (APIs) and Highly Potent Active Pharmaceutical Ingredients (HPAPIs) for the pharmaceutical industry. Minakem Corporation, founded in 2004 in France, specializes in producing APIs and HPAPIs. The company raised EUR 14. 5 million in funding on March 12, 2018, led by Minafin Group.

The firm has one notable deal and operates globally, with significant markets in Europe, North America, and Asia. Minakem specializes in the development and commercial production of Active Pharmaceutical Ingredients (APIs) and Highly Potent Active Pharmaceutical Ingredients (HPAPIs), catering to a diverse array of pharmaceutical applications. Their core offerings include custom development services for small molecule APIs, which are tailored to meet the specific needs of clients in the pharmaceutical industry. These products are utilized in the formulation of various therapeutic solutions, particularly in the treatment of serious conditions such as cancer, among others.

With over 60 years of experience, Minakem serves a global client base, exporting its products to 35 countries, including key markets in Europe, North America, and Asia. The company's commitment to quality is reflected in its extensive production network, which is supported by advanced quality assurance and control measures. Minakem generated revenue of EUR 152,730,136. 30 in 2022, with an EBITDA of EUR 21,308,875.

90. The company's revenue model is structured around B2B transactions, focusing on partnerships with pharmaceutical companies that require high-quality APIs for their drug development processes. Transactions typically involve long-term agreements with pharmaceutical firms, ensuring a consistent flow of business. Products like Fulvestrant and Vinorelbine are critical components of its revenue stream, as they are essential for treating various medical conditions.

Minakem plans to leverage recent funding of EUR 14. 5 million, raised in March 2018, to expand its product offerings and develop new APIs. The company aims to explore additional markets in Asia and North America by 2025 to enhance its global reach. These initiatives will focus on launching new products specifically designed for advanced therapies in oncology and other critical areas, ensuring that Minakem continues to meet the evolving needs of its pharmaceutical clients.